You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

Givinostat hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for givinostat hydrochloride and what is the scope of freedom to operate?

Givinostat hydrochloride is the generic ingredient in one branded drug marketed by Italfarmaco Spa and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Givinostat hydrochloride has fifty-eight patent family members in twenty-nine countries.

One supplier is listed for this compound.

Summary for givinostat hydrochloride
International Patents:58
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 15
Patent Applications: 2
DailyMed Link:givinostat hydrochloride at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for givinostat hydrochloride
Generic Entry Date for givinostat hydrochloride*:
Constraining patent/regulatory exclusivity:
TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS 6 YEARS OF AGE AND OLDER
Dosage:
SUSPENSION;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for givinostat hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
ItalfarmacoPhase 1
CromsourcePhase 2/Phase 3
ItalfarmacoPhase 2/Phase 3

See all givinostat hydrochloride clinical trials

US Patents and Regulatory Information for givinostat hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Italfarmaco Spa DUVYZAT givinostat hydrochloride SUSPENSION;ORAL 217865-001 Mar 21, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Italfarmaco Spa DUVYZAT givinostat hydrochloride SUSPENSION;ORAL 217865-001 Mar 21, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Italfarmaco Spa DUVYZAT givinostat hydrochloride SUSPENSION;ORAL 217865-001 Mar 21, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Italfarmaco Spa DUVYZAT givinostat hydrochloride SUSPENSION;ORAL 217865-001 Mar 21, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Italfarmaco Spa DUVYZAT givinostat hydrochloride SUSPENSION;ORAL 217865-001 Mar 21, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for givinostat hydrochloride

Country Patent Number Title Estimated Expiration
Australia 2012368818 Diethyl- [6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl) - naphthalen-2-yl-methyl] -ammonium chloride for use in the treatment of muscular dystrophy ⤷  Sign Up
Australia 2016349169 Physically and chemically stable oral suspensions of Givinostat ⤷  Sign Up
Peru 20181369 SUSPENSIONES ORALES ACUOSAS FISICA Y QUIMICAMENTE ESTABLES DE GIVINOSTAT ⤷  Sign Up
New Zealand 741467 Physically and chemically stable oral suspensions of givinostat ⤷  Sign Up
European Patent Office 2809313 CHLORURE DE DIÉTHYL-[6-(4-HYDROXYCARBAMOYL-PHÉNYL-CARBAMOYLOXY-MÉTHYL)-NAPHTALÈNE -2-YL-MÉTHYL]AMMONIUM POUR UNE UTILISATION DANS LE TRAITEMENT DE LA DYSTROPHIE MUSCULAIRE (DIETHYL- [6- (4-HYDROXYCARBAMOYL-PHENYL-CARBAMOYLOXY-METHYL) - NAPHTHALEN-2-YL-METHYL]-AMMONIUM CHLORIDE FOR USE IN THE TREATMENT OF MUSCULAR DYSTROPHY) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.